Abstract: Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.
Type:
Application
Filed:
February 22, 2018
Publication date:
July 5, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system FGF receptor homodimer.
Type:
Application
Filed:
May 10, 2016
Publication date:
June 21, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
June 19, 2018
Assignee:
Albert Einstein College of Medicine, Inc.
Inventors:
William Jacobs, Jr., Pablo A. Gonzalez Munoz, Betsy Herold, Christopher Petro
Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
Type:
Grant
Filed:
September 12, 2014
Date of Patent:
June 12, 2018
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: A microfluidic intravital window includes an intravital imaging window adapted for implantation adjacent target tissue of a live animal, and a microfluidic fluid source and delivery system physically integrated into the window for controlled delivery of fluids to target tissue via the window. The microfluidic fluid source and delivery system is self-contained and completely located within the intravital imaging window, and includes at least one preloaded fluid reservoir, at least one fluid port in fluidic communication with both the at least one preloaded fluid reservoir and the target tissue, and at least one light activated fluid flow control device situated between the at least one preloaded fluid reservoir and at least one fluid port, to facilitate simultaneous in vivo viewing and remotely controlled fluid delivery to the target tissue.
Type:
Application
Filed:
December 7, 2016
Publication date:
June 7, 2018
Applicants:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
James CASTRACANE, Logan BUTT, David Entenberg, Lauren Sfakis, John CONDEELIS
Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Type:
Application
Filed:
May 4, 2016
Publication date:
May 24, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
Type:
Application
Filed:
January 10, 2018
Publication date:
May 24, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
Abstract: Methods and products are provided for determining if a subject having a tumor is (i) at risk of metastasis of the tumor, or (ii) at risk of recurrence of the tumor after treatment of the tumor. Methods of treatment of cancer, tumors and metastasis are also provided.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
May 15, 2018
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
Type:
Grant
Filed:
November 10, 2016
Date of Patent:
May 1, 2018
Assignees:
Victoria Link Limited, Albert Einstein College of Medicine, Inc.
Inventors:
Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
Abstract: Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) I?B kinase (IKK?) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-?B) or (ii) Notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity’.
Type:
Application
Filed:
October 13, 2017
Publication date:
April 19, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Type:
Application
Filed:
April 26, 2016
Publication date:
April 19, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.
Type:
Application
Filed:
May 24, 2016
Publication date:
April 19, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
March 27, 2018
Assignees:
Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
Inventors:
Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
Abstract: Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.
Type:
Grant
Filed:
June 3, 2015
Date of Patent:
March 27, 2018
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: Fluorescent and non-fluorescent fusion tags derived from green fluorescent protein (GFP). The fusion tags harbor substitutions with respect to GFP that increase expression of target proteins to which the fusion tags are fused; increase solubility; prevent dimerization and oligomerization, particularly in oxidizing environments such as the endoplasmic reticulum (ER); and, in some cases, enhance fluorescence of the fusion tag itself. The substitutions include various combinations of substitutions at select cysteine residues in GFP, substitutions in or near the GFP chromophore, and/or other substitutions. The fusion tags can be used for increasing expression of target proteins for mass production thereof or as a fluorescent tag.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
March 20, 2018
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods and compositions are disclosed for rapid functional analysis of gene variants based on analysis of protein-protein and protein-nucleic acid interactions.
Type:
Application
Filed:
November 21, 2017
Publication date:
March 15, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.
Type:
Grant
Filed:
March 1, 2016
Date of Patent:
March 13, 2018
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
March 6, 2018
Assignees:
Albert Einstein College of Medicine, Inc., Sonacare Medical, LLC
Inventors:
Narendra T. Sanghvi, Chandan Guha, Russell James Fedewa, Roy Francis Carlson, Ralf Seip, Wo-Hsing Chen
Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
Type:
Application
Filed:
September 18, 2017
Publication date:
March 1, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.